✂️ CRISPR-Cas9
Step through the most powerful gene-editing tool ever devised: a guide RNA directs the Cas9 protein to a precise location in the genome, the double helix unwinds, 20 base pairs are interrogated one by one, both DNA strands are cut — then the cell repairs the break by error-prone NHEJ or precise HDR.
CRISPR-Cas9 Mechanism (Jinek et al., 2012)
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) was adapted from a bacterial immune system into a programmable genome-editing tool. The two key components are:
- Cas9 protein — a molecular scissor with two nuclease domains (RuvC and HNH), each cutting one DNA strand.
- Guide RNA (gRNA) — a ~100 nt RNA consisting of a 20-nt spacer (complementary to the target) fused to a scaffold that binds Cas9.
Cas9 first scans the DNA for a PAM sequence (5′-NGG-3′) on the non-template strand. Once found, it locally unwinds the helix and checks base-pair complementarity between the spacer and the target. A near-perfect match triggers cleavage 3 bp upstream of the PAM, creating a blunt-ended double-strand break (DSB).
The cell repairs the DSB by one of two pathways: NHEJ (Non-Homologous End Joining) — fast but error-prone, generating small indels that disrupt gene function — or HDR (Homology-Directed Repair) — precise correction using a donor template, but only active in dividing cells.
About CRISPR-Cas9 Genome Editing
This simulation walks through the seven-step CRISPR-Cas9 mechanism: the Cas9 protein and guide RNA (gRNA) assemble into a complex, scan the DNA for a PAM sequence (5'-NGG-3'), unwind the double helix to form an R-loop, interrogate all 20 nucleotides of the spacer for base-pair complementarity, and finally cleave both strands with the RuvC and HNH nuclease domains. Users can adjust the number of guide RNA mismatches and observe how cleavage efficiency drops exponentially according to the formula e^(-0.35 x mismatches). After cleavage, you can choose either NHEJ (error-prone ligation that creates indels) or HDR (precise template-guided repair).
CRISPR-Cas9 was adapted from a bacterial adaptive immune system and has become the dominant tool in modern genome engineering, with applications ranging from basic research and drug target validation to clinical gene therapies for sickle-cell disease and inherited blindness.
Frequently Asked Questions
What is CRISPR-Cas9 and how does it work?
CRISPR-Cas9 is a two-component genome-editing system consisting of the Cas9 endonuclease and a synthetic guide RNA (gRNA). The gRNA contains a 20-nucleotide spacer sequence that base-pairs with a complementary target in the genome, directing Cas9 to that exact location. Once bound, Cas9 cuts both strands of the DNA helix, creating a double-strand break that the cell must repair.
How do I use the simulation controls?
Click "Next" to advance through each mechanistic step, or press "Auto" to animate automatically. The "Mismatches" slider introduces base-pair mismatches between the guide RNA and the target, which lowers the cut efficiency displayed in the stats bar. After reaching Step 7, activate "NHEJ Repair" or "HDR Repair" buttons to see the two different outcomes of DNA break repair.
What is the PAM sequence and why does Cas9 need it?
The PAM (Protospacer Adjacent Motif) is a short DNA sequence — 5'-NGG-3' for the widely used SpCas9 — located immediately 3' of the target site on the non-template strand. Cas9 must first bind the PAM before it can unwind the DNA and check guide RNA complementarity. Without a valid PAM, Cas9 will not cleave even a perfectly matching sequence, which limits off-target activity genome-wide.
What is the mathematical relationship between guide RNA mismatches and cleavage efficiency?
Cleavage efficiency decreases exponentially with the number of mismatches: Efficiency = e^(-0.35 x mismatches). At zero mismatches efficiency is 100%; at 5 mismatches it falls to about 17%; at 8 mismatches it drops below 6%. The position of mismatches also matters — those in the "seed region" (roughly nucleotides 1-12 adjacent to the PAM) are far more disruptive than mismatches near the distal 5' end of the spacer.
What are NHEJ and HDR, and when does each pathway activate?
Non-Homologous End Joining (NHEJ) is active in virtually all cell cycle phases and rapidly ligates the broken ends, but often introduces small insertions or deletions (indels) that disrupt the reading frame — useful for gene knockouts. Homology-Directed Repair (HDR) uses a supplied donor DNA template to introduce precise edits, but is only efficient during the S and G2 phases of the cell cycle when a sister chromatid is available, making it less practical in post-mitotic tissues.
Is CRISPR-Cas9 used in actual medical treatments?
Yes. In late 2023 the US FDA approved Casgevy (exagamglogene autotemcel), the first CRISPR-based therapy, for sickle-cell disease and transfusion-dependent beta-thalassemia. The treatment edits patients' own stem cells ex vivo to reactivate fetal haemoglobin production. Additional CRISPR therapies are in clinical trials for inherited blindness (CEP290 mutation), certain cancers, and HIV.
Who discovered CRISPR-Cas9 gene editing and when?
The programmable use of Cas9 for genome editing was demonstrated in a landmark 2012 paper by Jennifer Doudna (UC Berkeley) and Emmanuelle Charpentier (then at Umea University), published in Science. They showed that a single guide RNA could direct Cas9 to cut a specific DNA target in vitro. The following year, Feng Zhang at the Broad Institute and other groups demonstrated editing in mammalian cells. Doudna and Charpentier were awarded the 2020 Nobel Prize in Chemistry for this discovery.
What other molecular biology simulations are related to CRISPR?
CRISPR editing connects closely to DNA Replication (which must occur for HDR to work), Protein Folding (the Cas9 protein undergoes conformational changes upon gRNA and DNA binding), Cell Division / Mitosis (HDR efficiency is cell-cycle-dependent), and Enzyme Kinetics (Cas9 behaves as a sequence-specific restriction enzyme with tunable specificity). The Membrane Diffusion simulation is relevant for understanding how CRISPR delivery vectors (lipid nanoparticles) cross the cell membrane.
How is CRISPR-Cas9 delivered into cells in practice?
Common delivery methods include viral vectors (especially adeno-associated virus, AAV, for in vivo delivery), lipid nanoparticles (LNPs, used in the Casgevy therapy), electroporation of ribonucleoprotein (RNP) complexes for ex vivo cell editing, and plasmid transfection for laboratory use. Each method involves trade-offs between efficiency, cell-type specificity, immune response, and cargo size — AAV has a ~4.7 kb packaging limit, which restricts some larger Cas9 variants.
What are the frontier applications and open challenges for CRISPR technology?
Active research frontiers include base editing (converting one DNA base to another without a double-strand break), prime editing (a "search and replace" approach using a reverse-transcriptase fusion), epigenome editing (using catalytically dead dCas9 fused to methyltransferases or demethylases), and CRISPRa/CRISPRi systems for gene activation or silencing without any DNA cut. Open challenges include efficient in vivo delivery to tissues such as the brain and muscle, reducing immunogenicity of bacterial Cas9 in humans, and regulatory frameworks for germline editing.